Vanta Bioscience
Vanta Bioscience Share Price Chart
Vanta Bioscience last traded at ₹20.42 (2026-10-13). Over the past month the stock moved -0.8%, three months the stock moved -16.5%, year the stock moved -15.8%. Its closing range over 52 weeks is ₹14.90 – ₹27.60, with the latest close 26.0% below the high.
Closing prices up to 2026-10-13.
About Vanta Bioscience
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]
Business Overview:[1][2][3] a) VBSL conducts R&D, clinical, and pre-clinical studies across genetic, animal, inhalation, and eco-toxicology. b) It is a preclinical contract research company offering safety assessment services to clients in pharma, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemicals. c) The company provides risk assessment services for APIs, excipients, extractables, leachables, and impurities arising from manufacturing or product degradation. d) VBSL also offers expert services to determine health-based exposure limits, including PDE, ADE, and OEL for pharmaceutical manufacturers.
Fundamentals
Quarterly Results
In the latest quarter (Mar 2026), Vanta Bioscience reported sales of ₹1.51 crore (-57.5%) and net profit of ₹1.93 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1.51 | 1.38 | 91.39 | 1.93 | 2.71 |
| Sep 2025 | 0.30 | -0.37 | -123.33 | -1.82 | -2.56 |
| Mar 2025 | 0.33 | -1.68 | -509.09 | -1.37 | -2.17 |
| Sep 2024 | 1.03 | -0.39 | -37.86 | -2.07 | -3.28 |
| Mar 2024 | 3.55 | -0.75 | -21.13 | -1.78 | -2.82 |
| Sep 2023 | 6.18 | 2.06 | 33.33 | -0.54 | -0.86 |
| Mar 2023 | 3.45 | -1.85 | -53.62 | -3.92 | -6.21 |
| Sep 2022 | 2.82 | -0.55 | -19.50 | -2.56 | -4.06 |
| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -46.6% | -27.5% | +14.9% | -17.6% | -63.5% | -90.4% | -95.1% | -57.5% |
| Operating profit growth | -130.9% | -184.9% | +38.3% | -137.9% | – | – | -118.0% | – |
| Net profit growth | -4366.7% | -1105.1% | -2800.0% | -2642.9% | – | – | – | – |
| EPS growth | -4160.0% | -1101.6% | -2966.7% | -2663.6% | – | – | – | – |
| OPM % | -19.5% | -53.6% | 33.3% | -21.1% | -37.9% | -509.1% | -123.3% | 91.4% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Vanta Bioscience reported sales of ₹1.82 crore (-7.1%) and net profit of ₹0.11 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1.82 | 1.02 | 56.04 | 0.11 | 0.15 |
| Mar 2025 | 1.96 | -4.25 | -216.84 | -4.77 | -7.56 |
| Mar 2024 | 9.72 | 1.31 | 13.48 | -8.61 | -3.68 |
| Mar 2023 | 5.83 | -2.39 | -40.99 | -10.44 | -10.27 |
| Mar 2022 | 9.40 | 3.47 | 36.91 | 0.14 | 0.14 |
| Mar 2021 | 9.82 | 3.95 | 40.22 | 0.45 | 0.71 |
| Mar 2020 | 13.75 | 4.37 | 31.78 | 1.01 | 1.58 |
| Mar 2019 | 12.08 | 3.27 | 27.07 | 0.70 | 1.11 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales growth | +13.8% | -28.6% | -4.3% | -38.0% | +66.7% | -79.8% | -7.1% |
| Operating profit growth | +33.6% | -9.6% | -12.2% | -168.9% | – | -424.4% | – |
| Net profit growth | +44.3% | -55.4% | -68.9% | -7557.1% | – | – | – |
| EPS growth | +42.3% | -55.1% | -80.3% | -7435.7% | – | – | – |
| OPM % | 31.8% | 40.2% | 36.9% | -41.0% | 13.5% | -216.8% | 56.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Vanta Bioscience.
Get Free AI Stock Analysis FREE →Latest News
No recent news available for Vanta Bioscience.
Frequently Asked Questions
What is Vanta Bioscience's current stock price?
Vanta Bioscience shares were last quoted at ₹20.42 (+0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Vanta Bioscience?
Vanta Bioscience has a price-to-earnings (P/E) ratio of 137.20 and a price-to-book (P/B) ratio of 0.70. The industry P/E is 5.80.
What is the 52-week high and low of Vanta Bioscience?
The 52-week high of Vanta Bioscience is ₹29.00 and the 52-week low is ₹14.71.
What is the market cap of Vanta Bioscience?
The market capitalisation of Vanta Bioscience is about ₹14.64 crore.
How did Vanta Bioscience perform in its latest quarterly results?
In the latest quarter (Mar 2026), Vanta Bioscience reported sales of ₹1.51 crore (-57.5%) and net profit of ₹1.93 crore, compared with the same quarter last year.
Is Vanta Bioscience a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Vanta Bioscience has a 3-year ROE of -16.00%, 3-year profit growth of 26.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Vanta Bioscience?
Promoters hold about 72.81% of Vanta Bioscience.
Which sector does Vanta Bioscience belong to?
Vanta Bioscience belongs to the Pharmaceuticals & Drugs sector.